Predictors of Virologic Failure and Resistance in HIV-Infected Patients Treated with Nevirapine-or Efavirenz-Based Antiretroviral Therapy

Parienti, Jean-Jacques; Massari, Véronique; Descamps, Diane; Vabret, Astrid; Bouvet, Elisabeth; Larouzé, Bernard; Verdon, Renaud
May 2004
Clinical Infectious Diseases;5/1/2004, Vol. 38 Issue 9, p1311
Academic Journal
Resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) increases with the wider use of this class of antiretroviral therapy. The association between adherence and resistance to NNRTI-based regimens is poorly understood. Predictors of virologic failure and resistance according to a baseline evaluation of nonadherence risk factors were determined in a cohort of 71 human immunodeficiency virus (HIV)-infected patients with early virologic response who received an NNRTI-based regimen. During the median follow-up of 29 months, 20 (28%) of 71 patients experienced virologic failure with an NNRTI-based regimen. Virologic failure was associated with repeated drug holidays (≥48 h of unplanned drug cessation), depression, younger age, and low adherence to therapy during baseline evaluation. Moreover, repeated drug holidays was the only risk factor for developing a major mutation conferring cross-resistance to the NNRTI class (hazard ratio, 22.5; 95% confidence interval, 2.8-180.3; P < .0001). Patients' previous adherence to therapy and drugs genetic barriers, not only the number of pills or doses involved, should be taken into consideration in the decision to simplify highly active antiretroviral therapy.


Related Articles

  • The financial and service implications of splitting fixed-dose antiretroviral drugs – a case study. Taylor, R; Carlin, E; Sadique, Z; Ahmed, I; Adams, EJ // International Journal of STD & AIDS;Feb2015, Vol. 26 Issue 2, p75 

    In 2010/2011, regional commissioners withdrew payment for the fixed-dose combination Combivir, forcing a switch to component drugs. This was deemed clinically acceptable and annual savings of £44 k expected. We estimated the true costs of switching and examined patient outcomes....

  • Efficacy and Safety of Once-Daily Regimens in the Treatment of HIV Infection. Molina, Jean-Michel // Drugs;2008, Vol. 68 Issue 5, p567 

    Early versions of highly-active antiretroviral therapy (HAART) characteristically involved complicated combinations of different drugs, which were taken as varying numbers of pills and as multiple doses each day. With the recent availability of once-daily treatment drugs, simpler regimens are...

  • Maraviroc: A Review of its Use in the Management of CCR5-Tropic HIV-1 Infection. Perry, Caroline M. // Drugs;2010, Vol. 70 Issue 9, p1189 

    Maraviroc (Celsentri®; Selzentry®) is a CCR5 coreceptor antagonist used in the treatment of CCR5-tropic HIV-1 infection. Administered orally twice daily, maraviroc, in combination with optimized background therapy regimens, showed good virological and immunological efficacy over 48 weeks...

  • Comparing HIV viral load assays and frequency of low level virological rebound in clinical practice. Briggs, R; Templeton, K; Fernando, I // International Journal of STD & AIDS;Dec2014, Vol. 25 Issue 14, p1029 

    Research suggests that some low-level virological rebound results occurring for no obvious clinical cause, in patients stable on antiretroviral therapy (ART), may be a consequence of the viral load assay used. We compared the relative frequency of clinically unexplained low-level virological...

  • A Simple, Dynamic Measure of Antiretroviral Therapy Adherence Predicts Failure to Maintain HIV-1 Suppression. Gross, Robert; Yip, Benita; Re III, Vincent Lo; Wood, Evan; Alexander, Christopher S.; Harrigan, P. Richard; Bangsberg, David R.; Montaner, Julio S. G.; Hogg, Robert S. // Journal of Infectious Diseases;10/15/2006, Vol. 194 Issue 8, p1108 

    Background. High levels of antiretroviral therapy adherence are important for human immunodeficiency virus type 1 (HIV-1) suppression, yet the magnitude of adherence required to maintain it is less well characterized. Furthermore, methods to accommodate changes in adherence over time are...

  • A single centre cohort experience with a new once daily antiretroviral drug. Stebbing, J.; Bower, M.; Holmes, P.; Gazzard, B.; Nelson, M. // Postgraduate Medical Journal;May2006, Vol. 82 Issue 967, p343 

    Background: Atazanavir, an azadipeptide protease inhibitor (PI) with once daily dosing, a lack of insulin resistance, lipid increase, and gastrointestinal toxicities, is approved in combination with other antiretrovirals for the treatment of patients infected with HIV. Unboosted atazanavir is...

  • Higher Short-Term Virologic Efficacy of Three-Class Versus Two-Class Highly Active Antiretroviral Salvage Therapy in HIV-Infected Patients. Baldanti, F.; Paolucci, S.; Maserati, R.; Maggiolo, F.; Pan, A.; Castelli, F.; Gulminetti, R.; Comolli, G.; Chiesa, A.; Gerna, G. // European Journal of Clinical Microbiology & Infectious Diseases;May2000, Vol. 19 Issue 5, p380 

    The efficacy of two-class versus three-class antiretroviral salvage treatment was analyzed retrospectively in 63 HIV-infected patients in whom highly active antiretroviral therapy failed. Twenty-eight patients (group A) received two-class therapy, and 35 patients (group B) received three-class...

  • Discontinuation of Antiretroviral Therapy in Patients with Chronic HIV Infection: Clinical, Virologic, and Immunologic Consequences. Mata, Rosario C.; Viciana, Pompeyo; de Alarcón, Arístides; López-Cortés, Luis F.; Gómez-Vera, Josefa; Trastoy, Mónica; Cisneros, José M. // AIDS Patient Care & STDs;Sep2005, Vol. 19 Issue 9, p550 

    To investigate the clinical, virologic and immunologic consequences of planned treatment interruptions in chronically HIV-infected patients. One hundred forty-one patients with undetectable viral load for at least 6 months and CD4+ T cells count greater than 500 per microliter were recruited....

  • ALLY 2. Hoyle, Brian; Sherman, Kenneth // MD Conference Express;Jul2015, Vol. 15 Issue 14, p9 

    Results of the ALLY 2 trial involving more than 200 patients co-infected with HIV/HCV shows the efficacy and safety of the combined 12-week use of daclatasvir and sofosbuvir, with sustained virologic response for 12 weeks of 97% after a 12-week treatment. The benefit for HCV infection does not...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics